Telomir Pharmaceuticals, Inc. (TELO) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Telomir Pharmaceuticals, Inc. is an early pre-clinical stage biopharmaceutical company incorporated in Florida. The company is developing TELOMIR-1, a novel small molecule designed to lengthen telomeres to treat age-related conditions in humans and canines. The reporting period covers the three and nine months ended September 30, 2024. The company completed its Initial Public Offering (IPO) on February 13, 2024, and trades on the Nasdaq Capital Market under the symbol "TELO".
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(5,990,733) | $(13,634,343) | $(3,744,649) |
| Loss Per Share (Basic/Diluted) | $(0.20) | $(0.46) | $(0.14) |
| Cash and Cash Equivalents (Sept 30, 2024) | $834,638 | ||
| Accumulated Deficit (Sept 30, 2024) | $(27,698,485) | ||
| Net Cash Used in Operating Activities (YTD) | $(4,464,620) | ||
| Net Cash Provided by Financing Activities (YTD) | $5,298,027 |
Material Changes vs. Prior Period
- Significant Increase in Expenses: General and Administrative (G&A) expenses surged to $5.4 million for Q3 2024 (vs. $0.1 million in Q3 2023) and $7.0 million YTD 2024 (vs. $0.2 million YTD 2023). This increase is primarily driven by new payroll costs for management and consultants post-IPO and a one-time stock-based compensation charge of approximately $4.8 million.
- Research and Development (R&D): R&D expenses increased to $0.6 million for Q3 2024 (vs. $0.3 million in Q3 2023) and $2.0 million YTD 2024 (vs. $1.4 million YTD 2023), reflecting continued toxicology studies and pre-clinical manufacturing.
- Elimination of Related Party Travel Costs: Related party travel costs, which totaled $1.3 million YTD 2023, were reduced to $0.4 million YTD 2024. The company ceased using a related party aircraft in March 2024.
- Interest Expense: Interest expense for YTD 2024 was $4.3 million, primarily due to the amortization of deferred financing costs related to warrants issued in connection with a prior related party line of credit. This compares to $0.9 million in YTD 2023.
- Capital Structure: The company raised approximately $5.8 million in net proceeds from its IPO in February 2024. Additionally, a new $5 million line of credit was secured from the Starwood Trust in September 2024, though no funds have been drawn as of the reporting date.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for at least 12 months from the filing date. With cash of approximately $0.8 million and a burn rate of roughly $4.5 million over the last nine months, the company expects to exhaust its resources by the third quarter of 2025 without additional financing.
- Development Timeline: The company anticipates filing its Investigational New Drug (IND) application with the FDA in the second half of 2025, with national phase filings expected in the third quarter of 2025.
- Financing Needs: Future operations and clinical trials are dependent on obtaining significant external funding. The company plans to conduct a capital raise in the near future.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024, due to material weaknesses. Remediation plans are underway, including hiring experienced accounting personnel.
- Risk Factors: Key risks include reliance on third-party suppliers for pre-clinical trials, potential delays due to geopolitical events (e.g., Israel-Hamas war), and the uncertainty of regulatory approval for TELOMIR-1.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $0.8 million cash balance against the projected burn rate and the timeline for the next capital raise.
- Stock-Based Compensation: Review the $4.8 million non-cash stock compensation expense included in G&A to understand its impact on reported net loss versus cash burn.
- Related Party Transactions: Assess the terms and necessity of the new $5 million Starwood Trust line of credit and the ongoing royalty agreement (8% of net sales) with MIRALOGX, LLC.
- Internal Controls: Monitor the progress of remediation efforts regarding the ineffective disclosure controls and procedures.
- Development Milestones: Track the progress of toxicology studies and the anticipated IND filing in late 2025 to gauge the path to clinical trials.